Hyper-truncated Asn355- And Asn391-glycans modulate the activity of neutrophil granule myeloperoxidase by Tjondro, Harry C. et al.
Hyper-truncated Asn355- And Asn391-glycans modulate the activity
of neutrophil granule myeloperoxidase
Downloaded from: https://research.chalmers.se, 2021-08-31 16:46 UTC
Citation for the original published paper (version of record):
Tjondro, H., Ugonotti, J., Kawahara, R. et al (2021)
Hyper-truncated Asn355- And Asn391-glycans modulate the activity of neutrophil granule
myeloperoxidase
Journal of Biological Chemistry, 296
http://dx.doi.org/10.1074/jbc.RA120.016342
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
RESEARCH ARTICLE EDITORS’ PICKHyper-truncated Asn355- and Asn391-glycans modulate the
activity of neutrophil granule myeloperoxidase
Received for publication, October 8, 2020, and in revised form, November 24, 2020 Published, Papers in Press, December 7, 2020,
https://doi.org/10.1074/jbc.RA120.016342
Harry C. Tjondro1,2,‡ , Julian Ugonotti1,2,‡ , Rebeca Kawahara1,2,‡ , Sayantani Chatterjee1,2,‡ , Ian Loke3 ,
Siyun Chen4 , Fabian Soltermann4 , Hannes Hinneburg1,2, Benjamin L. Parker5 , Vignesh Venkatakrishnan6 ,
Regis Dieckmann6 , Oliver C. Grant7 , Johan Bylund8 , Alison Rodger1,2 , Robert J. Woods7 ,
Anna Karlsson-Bengtsson6,9 , Weston B. Struwe4 , and Morten Thaysen-Andersen1,2,*
From the 1Department of Molecular Sciences and 2Biomolecular Discovery Research Centre, Macquarie University, Sydney, New
South Wales, Australia; 3Cordlife Group Limited, Singapore, Singapore; 4Department of Chemistry, University of Oxford, Oxford,
United Kingdom; 5Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia; 6Department of
Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg,
Sweden; 7Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA; 8Department of Oral Microbiology
and Immunology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and
9Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
Edited by Gerald HartMyeloperoxidase (MPO) plays essential roles in neutrophil-
mediated immunity via the generation of reactive oxidation
products. Complex carbohydrates decorate MPO at discrete
sites, but their functional relevance remains elusive. To this
end, we have characterised the structure–biosynthesis–activity
relationship of neutrophil MPO (nMPO). Mass spectrometry
demonstrated that nMPO carries both characteristic under-
processed and hyper-truncated glycans. Occlusion of the
Asn355/Asn391-glycosylation sites and the Asn323-/Asn483-
glycans, located in the MPO dimerisation zone, was found to
affect the local glycan processing, thereby providing a molec-
ular basis of the site-specific nMPO glycosylation. Native mass
spectrometry, mass photometry and glycopeptide profiling
revealed significant molecular complexity of diprotomeric
nMPO arising from heterogeneous glycosylation, oxidation,
chlorination and polypeptide truncation variants and a previ-
ously unreported low-abundance monoprotomer. Longitudinal
profiling of maturing, mature, granule-separated and
pathogen-stimulated neutrophils demonstrated that nMPO is
dynamically expressed during granulopoiesis, unevenly
distributed across granules and degranulated upon activation.
We also show that proMPO-to-MPO maturation occurs during
early/mid-stage granulopoiesis. While similar global MPO
glycosylation was observed across conditions, the conserved
Asn355-/Asn391-sites displayed elevated glycan hyper-
truncation, which correlated with higher enzyme activities of
MPO in distinct granule populations. Enzymatic trimming of
the Asn355-/Asn391-glycans recapitulated the activity gain and
showed that nMPO carrying hyper-truncated glycans at these
positions exhibits increased thermal stability, polypeptide
accessibility and ceruloplasmin-mediated inhibition potentialThis article contains supporting information.
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BY license (http://creativecommons.org/licenses/by/4.0/).relative to native nMPO. Finally, molecular modelling revealed
that hyper-truncated Asn355-glycans positioned in the MPO-
ceruloplasmin interface are critical for uninterrupted inhibi-
tion. Here, through an innovative and comprehensive
approach, we report novel functional roles of MPO glycans,
providing new insight into neutrophil-mediated immunity.
The myeloid lineage-specific myeloperoxidase (MPO) is an
essential component of the innate immune system associated
with many pathologies including cardiovascular diseases (1, 2),
rheumatoid arthritis (3) and multiple sclerosis (4). Mutations
in human MPO and genetic ablation in mice have repeatedly
been linked to enhanced pathogen infection (5–8).
While our knowledge of MPO has improved considerably
over the past decades (9–11), new fascinating facets of MPO
biology continue to emerge (12–14). Facilitated by its peroxi-
dase activity, MPO is known to catalyse the formation of
reactive oxidation products including hypochlorous acid
(HOCl) from chloride ions (Cl−) and hydrogen peroxide (H2O2),
substrates found in the maturing phagosomes (15, 16). From the
principal residence within the azurophilic (Az) granules, and to
a lesser extent within the specific (Sp) and gelatinase (Ge)
granules and in secretory vesicles and the plasma membrane
(collectively referred to as the Se/Pl fraction) of neutrophils
(17, 18), MPO is emptied into phagosomes or secreted through
degranulation upon neutrophil activation (19, 20). Within the
phagosome, MPO generates highly reactive hypohalous acids
and nitrogen dioxide, which readily react to form diverse
reactive oxygen species, key microbicidal and immune-
regulatory products of the neutrophil MPO-halide system.
The complex biogenesis and maturation of MPO have been
intensely studied (12, 21). Briefly, human MPO is translated as
a single 80 kDa signal peptide-containing polypeptide chain.
This preproMPO form undergoes extensive proteolytic pro-
cessing initiated by the removal of the signal peptide to formJ. Biol. Chem. (2021) 296 100144 1
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Figure 1. Comprehensive characterisation of neutrophil-derived myeloperoxidase (nMPO). A, protein architecture of the heme-containing diproto-
meric MPO (ααββ) (left). Each β-chain harbours five N-glycan sequons (orange) mapped on diprotomeric MPO (PDBID, 1D2V). Asn729 was left unoccupied
while characteristic glycans were added in silico to other sites (see D). B, fine structures and short-hand nomenclature of the nMPO N-glycans (Fig. S1,
Table S1 and Data S1). *Several hyper-truncated and/or trace N-glycans were only observed at the peptide level. ‡Multiple glycan isomers (designated a, b)
were identified. See key for glycan symbol nomenclature and linkage representation (37). C, non-glycan modifications of nMPO including Met (black) and
Trp (green) mono- and di-oxidation, Tyr (blue) mono-chlorination and polypeptide truncation variants (Fig. S2 and Data S2, A–B). D, site-specific N-glyco-
profile of nMPO (Fig. S3, Table S2 and Data S3, A–E). Prominent N-glycans at each site are in red. Data plotted as mean ± SD, n = 3, technical replicates.
E, intact mass analysis revealed limited α-chain heterogeneity arising from polypeptide truncation and Met251 and Met253 oxidation variants as supported
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EDITORS’ PICK: The glycobiology of neutrophil myeloperoxidaseapoproMPO. The enzymatically active proMPO form is
rapidly generated via heme acquisition in the endoplasmic
reticulum (ER) (22). Protease-driven polypeptide processing
then removes the propeptide and an internal hexapeptide,
which separates the light (α, 12.5 kDa) and heavy (β,
60–65 kDa) chains that remain covalently linked via the cat-
alytic heme. His261 and Arg405 (UniProtKB numbering used
throughout the paper) are key catalytic residues of the active
site that is formed around the heme moiety positioned be-
tween the α- and β-chains. By mechanisms that remain un-
clear, but presumably occurring within the Golgi, the α- and β-
chains are further processed and extensively post-
translationally modified before and/or after the formation of
the mature MPO diprotomer (ααββ, 150 kDa) that is con-
nected by a Cys319-Cys319 bridge (12).
The high-resolution crystal structures of neutrophil-derived
MPO (nMPO) with and without cognate and artificial ligands
have improved our knowledge of the structure of MPO, the
position of the heme and other hetero-atoms essential for
enzymatic activity (e.g., Ca2+) and the interactions to the
endogenous inhibitor ceruloplasmin (21, 23–27). Thirty years
ago, Nauseef and colleagues reported on the existence of five
sequons for asparagine-linked (N-linked) glycosylation
(Asn323, Asn355, Asn391, Asn483, Asn729) all located within
the mature MPO β-chain (28, 29). Most MPO crystal struc-
tures harbour remnants of N-glycan moieties, but our struc-
tural knowledge of the MPO glycosylation remains immature
since complex carbohydrates are usually incompletely resolved
with X-ray crystallography.
Four studies have reported on nMPO glycosylation over the
past decade (30–33). In those studies, mass-spectrometry-
based glycopeptide analyses detailed the site-specific mono-
saccharide compositions decorating nMPO. Compositions
corresponding to uncommon chitobiose core- and
paucimannosidic-type N-glycans as well as more conventional
oligomannosidic- and complex-type N-glycans were reported,
but neither the glycan fine structures and occupancy at each
site nor the biosynthesis and functional relevance of the N-
glycans carried by nMPO distributed across the neutrophil
granules were addressed. In fact, the molecular-level knowl-
edge of the roles of nMPO glycosylation is critically missing
despite recent reports suggesting that MPO glycans regulate
E-selectin binding (34), antigenicity (35, 36) and MPO enzyme
activity (31).
Here, we address this fundamental knowledge gap by charac-
terising the structure–biosynthesis–activity relationship of
nMPO and by profiling the dynamic expression, protein pro-
cessing and site-specific glycosylation of MPO from maturing,
mature, granule-separated and activated neutrophils. Integration
ofmass spectrometry, computational and biochemical assays was
used to provide new insight, from atomic to macromolecular
detail, into the intriguingly complex MPO glycobiology.by peptide data (Table S3A). F, i–ii, native MS of whole unfractionated nMPO re
matched the expected profile generated from approximately 300,000 predicte
of a previously unreported low-abundance monoprotomer (7%) and a high-aResults and discussion
Comprehensive characterisation of neutrophil-derived
myeloperoxidase
We first sought to unravel the molecular complexity of the
heme-containing MPO (ααββ), which adopts a complex
diprotomeric structure comprising two identical αβ proto-
mers, Figure 1A. Each β-chain harbours five sequons (Asn323,
Asn355, Asn391, Asn483, Asn729) enabling extensive N-
glycosylation of the protein surface. We applied our estab-
lished PGC-LC-MS/MS glycomics platform to fully define the
molecular structure of all N-glycans present on nMPO,
including identification of isomeric glycans, Figure 1B. Docu-
mentation for all reported structures has been provided,
Figure S1, Table S1 and Data S1. Uncommon monoantennary
complex-type (FA1G1S1a), under-processed oligomannosidic
(M5–M6) and hyper-truncated paucimannosidic (M2Fa-M3F)
and chitobiose core-type (GlcNAc1–GlcNAc1F) structures
were found to be characteristic N-glycans of nMPO. These
N-glycans are congruent with structures residing in the
neutrophil granules (38) and those carried by other granule-
resident glycoproteins including neutrophil cathepsin G and
elastase (32, 39, 40). No MPO O-glycans were detected in the
glycomics datasets.
Many non-glycan nMPO modifications including a total of
18 Met and nine Trp mono-/di-oxidations, two sites for Tyr
mono-chlorination and several polypeptide truncation variants
of both the α- and β-chains were identified using sensitive
peptide profiling facilitating a near-complete sequence
coverage of nMPO (α-/β-chain, 100.0%/99.8%), Figure 1C,
Figure S2 and Data S2, A–B. The observed polypeptide hyper-
oxidation, which is known to be mediated by the reactive
oxidising agents produced by MPO (30), plays recognised roles
in neutrophil function (41).
Further, site-specific glycoprofiling revealed an extensive
micro- and macro-heterogeneity of all five N-glycosylation
sites of nMPO, Figure 1D, Figure S3, Table S2 and Data S3,
A–E. In agreement with the previous four studies reporting
on the site-specific monosaccharide compositions of nMPO
(30–33), we found that Asn323 and Asn483 predominantly
carry paucimannosidic-type N-glycans (M2F–M3F), Asn355
and Asn391 carry oligomannosidic-type N-glycans (M5–M6)
while Asn729 is largely unoccupied or carries chitobiose
core-type (GlcNAc1–GlcNAc1F) N-glycans. We identified
low levels of mannose-6-phoshorylation on nMPO relative to
a recent study (33). Such discrepancies may arise from dif-
ferences in the methods used for the purification and/or
analysis of the glycoprotein. Notably, we observed very
similar glycosylation of all five sites of nMPO arising from
different sources including from unperturbed neutrophil
extracts (see detailed comparisons below) and acquired using
different techniques supporting an unbiased isolation and
characterisation of nMPO.vealed significant complexity of diprotomeric nMPO (ααββ) complexes that
d glycoproteoforms (Table S3B). G, mass photometry revealed the existence
bundance diprotomer (93%) of nMPO.
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(12,350–12,550 Da) arising from relatively few polypeptide
truncation and oxidation variants, presumably Met251 and
Met253, as supported by peptide data, Figure 1E and
Table S3A. The variable protein modifications identified at the
glycopeptide and peptide level were however reflected in our
native MS analysis of whole unfractionated nMPO as
demonstrated by significant molecular complexity of diproto-
meric nMPO (ααββ, 141.5–148.0 kDa, apex 143,958 Da),
which matched a published lower-resolution profile of intact
nMPO (apex 144,180 Da) (33) as well as a theoretical profile
generated from 300,000 glycoproteoforms predicted based
on quantitative peptide data (140.5–147.0 kDa), Figure 1F and
Table S3B. Native MS also indicated the existence of an nMPO
monoprotomer with a slightly lower-than-expected molecular
mass (αβ, 70–73 kDa, data not shown). Cooled non-reductive
SDS-PAGE followed by peptide profiling supported the pres-
ence of a maturely processed low-abundance nMPO monop-
rotomer, Figure S4. Single-molecule mass photometry, a
method capable of quantifying the assembly, binding affinities
and kinetics of protein complexes (42–44) confirmed that
nMPO exists as a low-abundance monoprotomer (αβ, 7%) and
high-abundance diprotomer (ααββ, 93%) with an apparent
mono-/diprotomer (αβ/ααββ) Kd of 50 pM, Figure 1G. The
biological role of the maturely processed monoprotomeric
MPO, which differs from the secreted monoprotomeric
proMPO reportedly elevated in blood in cardiovascular disease
(45, 46), remains unknown.
Tertiary and quaternary structural features explain the site-
specific N-glycosylation of MPO
The presence of vastly different glycan structures across
glycosylation sites on a given protein is interesting because the
protein experiences the same ensemble of glycan-processing
enzymes as it traffics the ER-Golgi pathways. We aimed to
identify the biochemical basis for this heterogeneity by first
investigating using in silico approaches the mechanisms
impacting the early-stage glycoprotein processing where MPO
enters the cis-Golgi as a fully folded monoprotomer (12). As
we have observed for other mammalian glycoproteins (47),
strong associations between the Asn accessibility on the MPO
surface and the degree of N-glycan type processing and core
fucosylation were identified, Figure 2A, Table S2 and
Table S4A. The relatively occluded Asn355- and Asn391-
glycosylation sites carried under-processed oligomannosidic-
type and afucosylated N-glycans as opposed to the surface
exposed sites (Asn323, Asn483, Asn729) (p = 3.5 × 10−13 and
5.7 × 10−13, respectively) carrying significantly more processed
N-glycans (p = 4.7 × 10−4 and 7.6 × 10−8) and core fucosylation
(both p = 1.3 × 10−7).
Further, in silico–assisted exploration of the late-stage MPO
processing within the N-glycan truncation pathway, a glycan-
processing pathway highly active in neutrophils (39, 48, 49),
demonstrated that the Asn483-glycans (and partly the
Asn323-glycans) undergo less truncation relative to the
Asn729-glycans, Figure 2Bi. The lower removal efficiency of4 J. Biol. Chem. (2021) 296 100144the outer β1,2-GlcNAc and α1,3-Man residues of the Asn483-
glycans relative to the Asn729-glycans (p = 3.5 × 10−5 and
1.1 × 10−8, respectively) correlated with a reduced solvent
accessibility of the β1,2-GlcNAc of Asn483-FA1 glycans upon
MPO dimerisation (p = 7.6 × 10−5), Figure 2Bii–iv and
Table S4B. The dimerisation-dependent occlusion of the
Asn483-glycans could be observed by the contact between (and
masking of) the Asn483-FA1 glycan and the surface of the other
αβ-protomer, Figure 2Bv. Intuitively, occlusion of the Asn483-
glycans restricts the N-acetyl-β-hexosaminidase (P06865/
P07686) and lysosomal α-mannosidase (O00754), key glycoside
hydrolases of the truncation pathway (48, 49), to access their
glycan substrates and, in turn, less efficiently catalyse β1,2-
GlcNAc and α1,3-Man removal of the Asn483-FA1 glycans.
The Asn323-glycan positioned near the MPO diprotomeric
interface was partially affected by MPO dimerisation as
indicated by amodestly impaired α1,3-Man removal of Asn323-
glycans (p = 0.014, Asn323 versus Asn729). The dimerisation-
dependent protection of the Asn323- and Asn483-glycans
from hydrolase-mediated truncation was supported by glyco-
peptide profiling of gel-separated mono- and diprotomeric
nMPO, Figure S4A. This analysis confirmed that the outer β1,2-
GlcNAc of the Asn323- and Asn483-glycans was more effi-
ciently removed of mono- rather than diprotomeric nMPO (p =
0.013 and 0.032, respectively), Table S5,A–B. Similar protective
effects could be observed for the Asn323-glycans of diproto-
meric MPO exhibiting a lower α1,3-Man removal efficiency
relative to monoprotomeric MPO (p = 0.008). Importantly,
similar processing of the Asn729-glycans, distal to the dimer-
isation interface, was observed on mono- and diprotomeric
nMPO (p ≥ 0.05). Collectively, and in line with current literature
(12), our in silico–assisted analyses show thatMPOdimerisation
takes place immediately before or quickly after MPO arrives in
the neutrophil granules, a maturation step that affects the pro-
cessing of the Asn323- and Asn483-glycans positioned at the
MPO diprotomeric interface. Follow-up studies aiming to
generate direct biochemical evidence of MPO from subcellular-
fractionated neutrophils are warranted to support our in silico–
guided observations of processes relevant to the biosynthesis of
MPO and the site-specific processing of its N-glycans.
Dynamics, distribution, processing and glycosylation of MPO
across neutrophil life stages
We next investigated the possible spatiotemporal expression
of nMPO and compartment-specific glycosylation during
neutrophil formation and activation. Dynamic expression of
MPO mRNA and protein during granulopoiesis was demon-
strated by re-interrogation of transcript and proteomics data
obtained from maturing neutrophils (50), Figure 3A. Consis-
tent with a previous protein profiling study of neutrophil
granules (18) and with the targeting-by-timing model that
describes the timely packaging of proteins in granules during
granulopoiesis (51), we show that MPO predominantly resides
in azurophilic (Az, 82.9%) granules while the specific (Sp) and
gelatinase (Ge) granules and the secretory vesicles/plasma
membrane (Se/Pl) contain less MPO, Figure 3B. The
Figure 2. In silico–assisted association studies inform on the molecular basis for the site-specific N-glycosylation of MPO. A, in silico–guided
investigation of maturely folded monoprotomeric MPO (as it appears in the early-stage processing) revealed correlations between (i) the Asn accessibility
(n = 5, different crystal structures) and the degree of (ii) N-glycan type processing plotted as the oligomannose-to-processed N-glycan conversion (n = 3,
technical replicates) and (iii) core fucosylation determined from possible FUT8 substrates based on nMPO glycopeptide profiling and solvent accessibility
data (n = 3, technical replicates) (Fig. 1D, Table S2 and Table S4A). The occluded Asn355 and Asn391 (green bars) carried mostly under-processed oligo-
mannosidic N-glycans and afucosylated N-glycans. Mean values for the accessible sites (Asn323, Asn483, Asn729) (broken lines) were statistically compared
with Asn355 and Asn391. iv, occluded Asn355 and Asn391 (green, depicted without glycans for clarity) and accessible Asn323, Asn729 and Asn483 (orange)
were mapped on monoprotomeric MPO (PDBID, 1D2V). B, i, exploration of the late-stage glycan processing of maturely folded MPO involving the N-glycan
truncation pathway (48, 49) demonstrated less truncation of the Asn483-glycans and partly Asn323-glycans as measured by the lower removal efficiency of
terminal residues including (ii) β1,2-GlcNAc (n = 3, technical replicates) and (iii) α1,3-Man residues relative to Asn729-glycans based on nMPO glycopeptide
data (n = 3, technical replicates) and (iv) a reduced β1,2-GlcNAc accessibility of FA1-conjugated Asn483 (orange) upon MPO dimerisation as determined in
silico (n = 5, different crystal structures) (Table S4B). Statistical comparisons were made to Asn729. v, illustration of the dimerisation-dependent occlusion of
the Asn483-glycan on diprotomeric MPO (1D2V). Contact between (and hence masking of) the Asn483-FA1 glycan and the protein surface of the other αβ-
protomer was observed (see zoom). The Asn323-glycan positioned near the diprotomeric interface was partially affected by MPO dimerisation. For all
panels, data plotted as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, *****p < 0.00005. See Figure 1 for key.
EDITORS’ PICK: The glycobiology of neutrophil myeloperoxidaseneutrophil granule distribution of MPO was determined from
four biological replicates using a conventional label-free
quantitation (LFQ) proteomics approach in which the LFQ
intensities of MPO were normalised across the neutrophil
granules. Neutrophils are known to release their proteinaceous
granule content via degranulation upon stimulation (20). To
expand on these findings, we monitored the release and
glycosylation patterns of degranulated MPO (Dg-MPO)
longitudinally upon neutrophil activation mediated by low-
level short-term infection by Staphylococcus aureus, an
opportunistic pathogen present in neutrophil-rich tissues un-
dergoing inflammation including, for example, the upper res-
piratory tract of individuals living with cystic fibrosis,
Figure 3C.Site-specific glycoprofiling of MPO from maturing, mature
(resting), granule-separated and pathogen-activated neutro-
phils showed that MPO carries relatively similar glycosylation
across the neutrophil life stages and under the conditions that
were analysed, Figure 3D. Similar MPO glycosylation patterns
of all five sites were observed across all granule types (corre-
lation coefficients, r > 0.95), which, as expected, matched the
glycosylation of unfractionated nMPO from resting neutro-
phils (PMN-nMPO, r > 0.95, see Figure S5 and Table S6 for all
data). Given our recent glycomics-based report of granule-
specific N-glycosylation of resting neutrophils (38) and the
observation of uniform N-glycosylation of neutrophil elastase
across granules (40), the observation of relatively similar N-
glycosylation of MPO distributed across granules indicatesJ. Biol. Chem. (2021) 296 100144 5
Figure 3. Dynamics, granule distribution, polypeptide processing, site-specific glycosylation and degranulation of MPO across the neutrophil life
stages. A, dynamic expression of MPO mRNA (n = 3, biological replicates) and protein (n = 4, biological replicates) during granulopoiesis. The relative MPO
expression levels, normalised to the PM-stage, were established by data re-interrogation (50). See key for nomenclature. B, quantitative proteomics of
granule-separated neutrophils (n = 4, biological replicates) showed an uneven MPO distribution across granules congruent with literature (18). C, S. aureus-
mediated neutrophil activation. Longitudinal profiling of the levels and glycosylation of released Dg-MPO (see panel F, D for data and controls). D, site-
specific glycoprofiling of MPO from maturing, resting (PMN-nMPO, see Fig. 1D), granule-separated, and activated neutrophils (average of n = 2–4
plotted, number of biological replicates is indicated). Prominent N-glycans at each site were plotted (Fig. S5 and Table S6). The MPO glycosylation of
maturing neutrophils was determined by data re-interrogation (50). See key for intensity scale and biological replicates and Figure 1 for short-hand
nomenclature of glycans. E, longitudinal tracking of the proMPO-to-MPO conversion within maturing, mature, and granule-separated neutrophils. Rela-
tive levels of peptides arising from the proMPO regions (normalised to PM-stage) were plotted.
ˇ
ProMPO levels were determined from the intensity of
peptide pairs arising from proMPO and mature MPO. The data do not discriminate apoproMPO and proMPO. See insert for schematics of MPO polypeptide
maturation (average of n = 4, biological replicates). F, S. aureus-mediated activation of neutrophils (MOI 1:5) demonstrating a rapid time-dependent and cell
death-independent degranulation of Dg-MPO as measured by ELISA and LDH release assays. Controls (a–c, mean plotted as broken lines) were included for
both assays (n = 3, technical replicates). G, sequence alignment showed that Asn355 and Asn391 are conserved sequons across the human peroxidases
implying functional importance. See Figure S6 for sequence alignment to mammalian MPO. H, hyper-truncated GlcNAcβAsn and absent glycosylation were
elevated features at (i) Asn355 and (ii) Asn391 of Se/Pl-MPO relative to MPO from other granules (n = 4, biological replicates). For all panels, data plotted as
mean ± SD. ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, *****p < 0.00005. EPO, eosinophil peroxidase; LPO, lacto-
peroxidase; TPO, thyroid peroxidase.
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EDITORS’ PICK: The glycobiology of neutrophil myeloperoxidasethat both the different granule protein populations and dif-
ferential glycan processing of the proteins trafficking to the
individual granules contribute to the compartment-specific
glycosylation of neutrophils.
MPO glycoprofiling of maturing neutrophils, facilitated by
data re-interrogation (50), indicated that PM-MPO and MPO
from all subsequent neutrophil development steps surprisingly
carry fully processed N-glycosylation signatures at all sites (r >
0.93). Supporting the MPO maturation in early-stage gran-
ulopoiesis, longitudinal profiling of the proMPO-to-MPO
conversion within maturing, mature and granule-separated
neutrophils showed a near-complete pro- and hexapeptide
removal from metamyelocyte-derived MPO (MM-MPO, 1%
proMPO) and from MPO of more advanced cellular matura-
tion stages, Figure 3E. Our data could not discriminate be-
tween the apoproMPO and proMPO forms (without and with
heme, respectively), but the unprocessed form observed in this
study is likely proMPO since heme acquisition reportedly
occurs rapidly in the ER (22). Taken together, our data indicate
that the heavily processed MPO undergoes rapid glycan and
polypeptide maturation upon expression at the PM stage
during granulopoiesis.
In addition to the characterisation during neutrophil
maturation, we also glycoprofiled MPO during pathogenic
infection. S. aureus–mediated activation of neutrophils per-
formed at sub-stoichiometric levels to simulate the relatively
weak chronic infection levels experienced by individuals with
cystic fibrosis and to prevent cell lysis (MOI 1:5) demonstrated
a rapid (30–120 min) time-dependent and cell-death-
independent degranulation of Dg-MPO, Figure 3F. The Dg-
MPO carried similar glycosylation to PMN-nMPO (r > 0.91)
indicating a glycoform-independent degranulation process of
the protein. It remains unknown if the weakly altered glycans
observed at selected sites (e.g. Asn355, r = 0.81) functionally
impact the pathogen-killing ability of MPO or result from
technical variation of the analytically challenging site-specific
profiling of MPO directly from biological mixtures (52).
Sequence alignments showed that Asn355 and Asn391 are
conserved sequons within the family of human peroxidases
and within MPO expressed across mammalian species,
Figure 3G and Figure S6. The sequon conservation of Asn355
and Asn391, which recently was strengthened by the obser-
vation of similar glycosylation patterns of these two sites on
human and mouse MPO (53), implies a functional relevance of
the Asn355- and Asn391-glycans. Interestingly, absence of
glycosylation and hyper-truncated GlcNAcβAsn were found to
be elevated features of Se/Pl-MPO at Asn355 (p = 9.2 × 10−5
and 0.04, respectively, Se/Pl- versus Az-MPO) and Asn391 (p =
0.022 for GlcNAcβAsn) relative to MPO from other granules,
Figure 3H. It may be speculated that the absence or hyper-
truncation of glycans positioned at Asn355 and Asn391 of
Se/Pl-MPO arises from the action of endoglycosidase
H- (Endo H-) and peptide:N-glycosidase F-like hydrolases e.g.
di-N-acetylchitobiase (Q01459) and N(4)-(beta-N-acetylglu-
cosaminyl)-L-asparaginase (P20933) and/or other glycoside
hydrolases of the truncation pathway that may be co-expressed
and co-sorted with MPO trafficking to these compartments(48, 54). Regardless of the underlying biosynthetic processes,
the position-specific enrichment of uncommon glycan signa-
tures in specific compartments of the neutrophil is intriguing
and without precedence in the literature.
Hyper-truncated Asn355- and Asn391-GlcNAc residues
allosterically augment MPO activity
Next, we explored the function of MPO glycans, which are
unlikely to interfere directly with the substrate–product ex-
change to the heme-containing catalytic site as these are
located distal to the active site, Figure 4Ai. We therefore
investigated the modifications of the catalytic site using
peptide-focused LC-MS/MS. Hyper-oxidation of Met251,
Met253 and Trp255 lining the catalytic site was observed
indicating extensive auto-oxidation that may impact the MPO
activity by possibly reconfiguring the active site, Figure 4Aii.
Activity assays performed on granules of Donor a–b neutro-
phils fractionated on two-layered density gradients were then
used to demonstrate that Se/Pl-MPO exhibits a higher chlo-
rination activity (3.7–9.0-fold) and oxidation activity
(5.0–51.5-fold, Se/Pl- versus Az-MPO) than MPO from other
granules, Figure 4Aiii and Table S7. In support, peptide anal-
ysis of granules from Donor c–f neutrophils fractionated on
three-layered density gradients confirmed that Se/Pl-MPO
exhibits a higher chlorination activity than MPO from other
granules based on a higher Tyr chlorination level of the
granule proteins (p = 4.7 × 10−3, Se/Pl- versus Az-MPO),
Figure 4Aiv and Table S8.
Endo H-treatment of nMPO under native conditions pro-
duced an Asn355- and Asn391-GlcNAc-rich glycophenotype
mimicking the enriched glycoforms of Se/Pl-MPO, Figure 4Bi.
As discussed further below, LC-MS/MS-based characterisa-
tion validated that the oligomannose-rich Asn355- and
Asn391-glycans were fully converted to GlcNAcβAsn while
the processed N-glycans in other positions were Endo H-
insensitive, Figure S7. Excitingly, the Endo H-treated nMPO
exhibited higher chlorination and oxidation activity than un-
treated nMPO as established using three different activity as-
says (3.4–5.8×, all p < 0.005), Figure 4Bii and Table S9, A–C.
The molecular basis of the intriguing glycoform-dependent
MPO activity was investigated using CD and MD simulations
of relevant MPO glycoforms (WT and P1–P3, see Table S10,
A–B for overview of the modelled MPO glycoforms). Endo
H-treated nMPO (P1) and untreated nMPO (WT) displayed
indistinguishable secondary structure profiles rich in helical
content as reported (55, 56) based on CD data and predictions
based on MD data, Figure 4C and Table S11, A–B. Notably,
however, the Endo H-treated nMPO showed a higher initial
melting temperature (72 C) than untreated nMPO (60 C) as
determined by CD208 nm, Figure 4Di and Table S11C. Both
glycoforms completed their transition by 88 C, though about
half the helical structure remained at this temperature. Thus,
our data suggest that Endo H-treated nMPO displays an
enhanced thermal stability relative to native nMPO. MD
indicated that the relatively higher thermal stability of Endo H-
treated nMPO was accompanied by a significantly higher
global polypeptide accessibility relative to nMPO, Figure 4DiiJ. Biol. Chem. (2021) 296 100144 7
Figure 4. Hyper-truncated Asn355- and Asn391-GlcNAc signatures positioned distal to the catalytic site augment the MPO activity. A, i, The MPO
N-glycans are positioned distal to the catalytic site. Zoom: Oxidation-prone Met251, Met253 and Trp255 (yellow) in the heme-containing (orange) catalytic
site. Mapped on monoprotomeric MPO (PDBID, 1D2V), see Figure 1 for key. ii, hyper-oxidation of Met251, Met253 and Trp255 indicates extensive auto-
oxidation. iii, Se/Pl-MPO from Donor a–b neutrophils displayed a higher chlorination and oxidation activity than MPO from other granules (Table S7).
Adjusted for MPO levels, n = 3, technical replicates. iv, relative Tyr chlorination level of proteins from granules fractionated with high resolution of neu-
trophils from Donor c–f (Table S8). Adjusted for total protein and MPO levels, n = 4, biological replicates. B, i, Endo H-treatment of nMPO produced an
Asn355- and Asn391-GlcNAc glycophenotype (mimicking the enriched GlcNAcβAsn signatures of Se/Pl-MPO, see Fig. 3H) as validated using LC-MS/MS
(Fig. 5B). Main glycoforms are depicted for each site. ii, the Endo H-treated nMPO exhibited a higher enzyme activity than native nMPO based mea-
surements of the HOCl production (activity assay 1) and the oxidation rate (activity assays 2–3) (all assays, n = 3, technical replicates) (Table S9, A–C). C, Endo
H-treated and untreated nMPO displayed indistinguishable secondary structure profiles based on (i) CD profiling (Table S11, A–B) and (ii) MD-based
predictions. D, relative to native nMPO (WT), Endo H-treated MPO (P1, see Table S10, A–B for overview of the modelled MPO glycoforms) showed (i)
higher thermal stability as determined by CD208 nm (arrows indicate initial melting temperatures) and (ii) greater global polypeptide accessibility based on
MD data (n = 5, technical replicates) (Figs. S8 and S9). Key: a–e and i–ii indicate positions of the MPO glycosylation sites and key catalytic residues,
respectively. For panel Bii, Ci, and Di: ^Endo H-treated nMPO data were normalised based on Endo H only control data to enable comparison to untreated
nMPO. For all panels: Data plotted as mean ± SD, ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, *****p < 0.00005.
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throughout the polypeptide chains, but with particular “hot-
spots” of dramatically enhanced accessibility of residues C-
terminal to Asn355 and Asn391 (labelled b–c) and distal to the
heme and active site residues (i–ii, His261/Arg405), were
observed for P2 (mimicking the Se/Pl-MPO-enriched glyco-
forms). The P3 glycoform carrying semi-truncated N-glycans
at Asn355 and Asn391 (M2–M3) did not show elevated8 J. Biol. Chem. (2021) 296 100144accessibility relative to nMPO suggesting that absence or
hyper-truncation of glycans positioned at Asn355 and
Asn391 is required to allosterically impact the global MPO
structure and augment activity. In support, prolonged contacts
were consistently observed between the β1,4-GlcNAc
and β1,4-Man of the trimannosylchitobiose core (Man-
β1,4GlcNAcβ1,4GlcNAcβAsn) and the polypeptide region
immediately C-terminal to Asn355 and Asn391 during the MD
Figure 5. Hyper-truncated Asn355-glycans augment the ceruloplasmin-mediated MPO inhibition. A, schematics of the glycoform-dependent ceru-
loplasmin-based inhibition of Endo H-treated and untreated nMPO. Our data support that nMPO glycoforms carrying hyper-truncated GlcNAc signatures at
Asn355 and Asn391 enable a closer contact to the natural MPO-inhibitor ceruloplasmin thereby sterically precluding an efficient substrate-product ex-
change to the catalytic site of nMPO as illustrated. Common glycans decorating Asn323, Asn355 and Asn391 in proximity to the MPO-ceruloplasmin
interface and the HOCl-producing active site (yellow star) are portrayed. B, glycopeptide data (selected EICs) demonstrating complete conversion of
Asn355-M6 and Asn391-M6 to GlcNAcβAsn upon Endo H-treatment (Fig. S7). The Endo H-insensitive Asn323-M2F was included as a control. C, the
chlorination (i) and relative oxidation (ii–iii) levels of native nMPO (left graphs) and Endo H-treated nMPO (right) incubated with (gray bars) and without
(black) serum ceruloplasmin (Cp) were determined in technical triplicates using activity assay 1-3, respectively (Table S9, D–F). The activity data of nMPO and
Endo H-treated nMPO (black bars) already shown in Figure 4B, ii were included again to allow for a comparison to the activity data of the Cp-treated nMPO.ˇ
Endo H-and Cp-treated nMPO data were normalised based on Endo H and Cp only control data to enable comparison to untreated nMPO (for all assays,
n = 3, technical replicates). D, MD data of Asn323-M2F (green), Asn355-M6 (magenta) and Asn391-M6 (red) modelled on a crystal structure of the
ceruloplasmin–MPO complex (PDBID, 4EJX) demonstrated that Asn355-M6 and not Asn355-GlcNAc clashes with ceruloplasmin (see zoom). Data plotted as
mean ± SD, ns, not significant (p ≥ 0.05), *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001.
EDITORS’ PICK: The glycobiology of neutrophil myeloperoxidasesimulation of glycans elongated beyond the GlcNAcβAsn at
these positions (data not shown). Such glycan–protein con-
tacts, which may modulate protein stability and structure, are
particularly interesting given that Asn355 and Asn391 are
positioned on flexible loops proximal to the active site. The
MD data including RMSD-based mobility measurements,
however, were insufficiently sensitive to unravel the molecular
basis of the observed structure–activity relationships of gly-
cosylated MPO in greater details, which, consequently, await
future exploration, Figure S8D.Hyper-truncated Asn355-glycosylation enhances
ceruloplasmin-mediated MPO inhibition
The impact of glycosylation on MPO inhibition by cerulo-
plasmin, an endogenous inhibitor of MPO (27), was explored
by comparing the relative activity of Endo H-treated and un-
treated nMPO in the absence and presence of serum-derived
ceruloplasmin, Figure 5A. As already discussed above
(Fig. 4B), the Endo H-treatment completely converted the
oligomannose-rich Asn355 and Asn391 to GlcNAcβAsn-
containing sites while sites containing processed glycans (e.g.J. Biol. Chem. (2021) 296 100144 9
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chlorination and relative oxidation rates of Endo H-treated
and untreated nMPO were determined with and without
equimolar ceruloplasmin using the three independent activity
assays already described above, Figure 5C and Table S9, D–F.
Activity assays 1 and 3 showed significant ceruloplasmin-
mediated inhibition of Endo H-treated nMPO (p = 3.8 ×
10−4 and 8.5 × 10−5) while untreated nMPO exhibited weak to
no ceruloplasmin-mediated inhibition. For activity assay 2, an
activity gain was observed for untreated nMPO upon the
addition of ceruloplasmin; this unexplained activity gain was
quenched for the Endo H-treated nMPO. The molecular
mechanisms underpinning the glycoform-dependent MPO
inhibition by ceruloplasmin were explored using MD data of
relevant Asn323-, Asn355- and Asn391-glycans modelled on a
structure of the ceruloplasmin–MPO complex (PDBID, 4EJX),
Figure 5D. Modelling demonstrated that only Asn355 is
positioned directly in the MPO:ceruloplasmin interface, and,
importantly, that Asn355-M6 and not Asn355-GlcNAc steri-
cally clashes with ceruloplasmin thereby providing a molecular
basis for the glycoform-dependent inhibition of MPO by
ceruloplasmin.
Conclusions
We have characterised the structure–biosynthesis–activity
relationship of neutrophil granule MPO and longitudinally
profiled the spatiotemporal expression, protein processing,
site-specific glycosylation and degranulation of MPO from
maturing, mature, granule-separated and pathogen-activated
neutrophils from healthy donors. Powered by multi-omics
tools, our quantitative and longitudinal data add important
molecular-level knowledge to our growing understanding of
the complex MPO biology governing many innate immune
processes central to human health and disease (41, 57).
Complementary mass spectrometry and novel mass
photometry approaches helped unravel the molecular
complexity displayed by the heavily glycosylated and post-
translationally modified nMPO. Critically, nMPO is site-
specifically modified by unique glycans that are rarely
reported in human glycobiology, but indeed are common to
neutrophils including the hyper-truncated paucimannosidic-
and chitobiose core-type N-glycans (48, 49), as well as elab-
orate oxidation, chlorination and polypeptide truncation
variants. The structural glycan data presented herein align
with and significantly expand on the existing knowledge base
(30, 31, 33) by providing not only details of the glycan iso-
mers, but also the molecular mechanisms contributing to the
distinctive site-specific MPO glycosylation. Several protein
factors including the spatial environment and dimerisation
status were found to affect the local N-glycan processing
producing a position-specific glycan-code, which, intrigu-
ingly, was found to impact both the MPO structure and the
activity and inhibition potential of the enzyme. The rarely
reported GlcNAcβAsn-type glycans were elevated at strategic
sites that are important for the activity and ceruloplasmin-
mediated inhibition of MPO within mobile compartments
of neutrophils.10 J. Biol. Chem. (2021) 296 100144While glycans are widely recognised to modulate the func-
tions and the physicochemical properties of proteins including,
amongst others, the stability, solubility and receptor binding
potential of proteins and their susceptibility to proteolysis
(58–63), the literature seemingly harbours relatively few ex-
amples of glycans impacting the activity of enzymes such as
bovine pancreatic ribonuclease (64) and human tissue plas-
minogen inhibitor (65, 66). We were unable to find any studies
reporting on hyper-truncated N-glycans modulating both the
enzyme activity and inhibition potential in the literature.
Taken together, our data suggest that neutrophils dynami-
cally produce, process, package, store and, upon activation,
release a repertoire of related MPO glycoforms displaying a
continuum of different activity and inhibition profiles. The
strategically positioned Asn355 glycosylation site carrying both
hyper-truncated and elongated N-glycans was found to be
particularly important for MPO function, a finding that may
guide future glycoengineering efforts aiming to generate
therapeutically relevant recombinant MPO products with
tuneable activity and inhibition potential tailored to specific
biomedical applications involving persistent and severe path-
ogen infections.
In conclusion, this study has provided new molecular-level
insights into the intriguingly complex glycobiology of MPO
of importance to fundamental neutrophil biology and MPO-
mediated immune processes central to human health and
disease.
Experimental procedures
Donors, neutrophil isolation, granule separation, activation
and maturation of neutrophils
Donors
Six 40 ml donor pools of buffy coats each obtained from
four healthy individuals (six donor pools × four individuals/
pool × 10 ml buffy coat/individual) were provided by The
Blood Center, Sahlgrenska University Hospital, Gothenburg,
Sweden. These six donated buffy coat pools are referred to as
‘Donor a–f’, see Table S12 for an overview of the donor
samples, how they were handled and the conducted assays.
Further, for the experiments involving pathogen-based acti-
vation of neutrophils, three 20 ml non-pooled buffy coats
obtained from three healthy individual were provided by The
Blood Center, Sahlgrenska University Hospital, Gothenburg,
Sweden. These non-pooled buffy coat samples are referred to
as “Donor g–i”. Details of the donors of maturing neutrophils
used to establish the protein and transcript profiles of imma-
ture neutrophils undergoing granulopoiesis based on data
reinterrogation (see details below) have been published (50).
Neutrophil isolation
Primary neutrophils were isolated from the buffy coat from
Donor a-i as previously described (18, 67). Briefly, the eryth-
rocytes were removed by dextran (1%, w/v) sedimentation.
Monocytes and lymphocytes were removed by centrifugation
at 400g, 4 C, 30 min on a Ficoll–Paque density gradient. The
cells were then washed two times for 30 s in Krebs–Ringer
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the remaining erythrocytes by hypotonic lysis. The neutrophils
were then spun at 200g, 4 C, 10 min and resuspended in the
KRG buffer. The total neutrophil count for each of the buffy
coat pools was 109, the purity was >95% and the viability was
>99% as measured by a haematology cell counter (Sysmex),
trypan blue stain microscopy and Annexin V and propidium
iodide staining using flow cytometry (Thermo Fisher Scienti-
fic), respectively. Aqueous diisopropyl fluorophosphate was
added to a final concentration of 5 mM and kept in the cell
suspension for 5 min before excess protease inhibitor was
removed by centrifugation at 200g, 4 C, 6 min.
Granule separation
Granules were separated from resting neutrophils isolated
from Donor a–f. For this purpose, the plasma membranes of
the isolated neutrophils were gently disrupted without
compromising the integrity of the granule membranes using
nitrogen cavitation employing scientific-grade nitrogen
(≥99.99% purity, v/v) in a Parr bomb. The released granules
from Donor a-b neutrophils were crudely separated using a
two-layered Percoll separation method while the released
neutrophil granules from Donor c-f were subjected to a three-
layered Percoll separation method facilitating high-resolution
granule separation as described previously (67, 68). The
granule fractionation was validated using granule markers (69),
see Extended experimental procedures for details. Granules
were lysed and protein extracts collected.
Neutrophil activation, MPO degranulation and determination of
cell death
Resting neutrophils (Donor g–i) were inoculated with
S. aureus (LS1, multiplicity-of-infection (MOI) 1:5, bacter-
ia:neutrophils), 37 C, 0–120 min. Resting neutrophils without
S. aureus inoculation and with cytochalasin B/ionomycin
(CytB/I) and Triton-X 100 stimulation served as activation and
a cell death control, respectively. Degranulated MPO
(Dg-MPO) and cell death were monitored longitudinally in
supernatants using ELISA (ICL LAB) and lactate dehydroge-
nase (LDH) release using the Cytotoxicity Detection KitPLUS
(Sigma), see Extended experimental procedures for details.
Maturing neutrophils
Granulopoiesis-related protein and transcript data obtained
from maturing neutrophils isolated from four different matu-
ration stages were retrieved from a publicly available data set
(50). Immature neutrophils were isolated in their different
maturation stages by fluorescence-activated cell sorting from a
pool of myeloid progenitor cells derived from the bone
marrow of four healthy donors including promyelocytes and
myelocytes (collectively referred to as PMs), metamyelocytes
(MMs), immature neutrophils with band-formed nuclei (BNs)
and mature neutrophils with segmented nuclei (SNs). Circu-
lating (mature) neutrophils (polymorphonuclear cells, PMNs)
derived from blood from the same four donors were also
investigated, see Extended experimental procedures for details.Neutrophil-derived MPO
Human neutrophil-derived MPO (nMPO, UniProtKB,
P05164, >95% purity) was from pooled donor blood (Lee
BioSolutions). The purity, concentration, structural integrity
and enzyme activity of nMPO were confirmed prior to anal-
ysis, see Extended experimental procedures for details.
Glycan profiling
N-glycans were released from nMPO using Elizabethkingia
miricola peptide-N-glycosidase F (Promega) (70). Reduced N-
glycans were profiled in technical triplicates using porous
graphitised carbon (PGC) liquid chromatography–tandem
mass spectrometry (LC-MS/MS) in negative ion polarity on
an LTQ Velos Pro ion trap mass spectrometer (Thermo Sci-
entific) (71). Glycan fine structures were manually elucidated
(72). RawMeat v2.1 (Vast Scientific) and GlycoMod (Expasy)
aided the process. N-glycans were quantified from area-under-
the-curve (AUC) measurements of extracted ion chromato-
grams (EICs) using Skyline v20.1.0.76 (72), see Extended
experimental procedures for details.
Glycopeptide profiling
Glycopeptides and peptides were profiled from (i) nMPO,
(ii) mono- (αβ) and diprotomeric (ααββ)-separated nMPO, (iii)
endoglycosidase H- (Endo H-) treated and untreated nMPO,
(iv) granule-separated MPO and (v) Dg-MPO released from
pathogen-activated neutrophils. For (i) reduced and carbami-
domethylated nMPO was digested in technical triplicates using
sequencing-grade porcine trypsin (Promega), (ii) mono- and
diprotomeric nMPO were separated in technical triplicates
using non-reductive SDS-PAGE on a pre-cast 4–12% gradient
gel (Invitrogen). Separations were performed using a constant
potential of 120 V, 45 min and were carried out on ice to
prevent spontaneous dissociation of diprotomeric nMPO.
Protein bands were in-gel trypsin digested, (iii) Endo H-treated
and untreated nMPO (see below) were applied separately to
SDS-PAGE. The β-chains (53–58 kDa) were in-gel trypsin
digested, (iv) isolated granule fractions were briefly introduced
into SDS-PAGE gels. Bands containing all granule proteins
were in-gel trypsin digested, and (v) released proteins were
acetone precipitated, reduced, alkylated and in-solution
trypsin digested. All peptide mixtures were desalted before
LC-MS/MS.
Peptides were separated using C18 chromatography and
detected using a Q-Exactive HF-X Hybrid Quadrupole-
Orbitrap mass spectrometer (Thermo Scientific) in positive
ion polarity. LC-MS/MS data were searched against the ca-
nonical human MPO (P05164) and/or the human proteome
(all reviewed UniProtKB entries) using Byonic v3.6.0 (Protein
Metrics) and MaxQuant v1.6, see Table S13 for overview.
Variable modifications including Met and Trp mono-/di-
oxidation, Tyr mono-/di-chlorination and N-glycan libraries
were included in the searches. Glycopeptides with Byonic PEP-
2D scores <0.001 were considered and manually validated
(73). Non-glycan modified peptides were filtered to peptide-to-
spectral matches and protein false discovery rates <0.01 toJ. Biol. Chem. (2021) 296 100144 11
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peptides were profiled based on AUCs of monoisotopic EICs
of glycopeptide precursors using Skyline v20.1.0.76 or Xcalibur
v2.2 (Thermo Scientific). Non-glycosylated peptides and pro-
teins were quantified based on precursor intensities using
MaxQuant (74), see Extended experimental procedures for
details.
Intact nMPO analysis using native MS and mass photometry
Top-down/native MS was performed of (i) the intact
α-chain of nMPO and (ii) intact nMPO. For (i) nMPO was
reduced, desalted and injected on a C4 LC column connected
to an Agilent 6538 quadrupole-time-of-flight mass spectrom-
eter operating in high-resolution positive polarity mode. Mass
spectra were deconvoluted using MassHunter vB.06 (Agilent
Technologies). Assignments were guided by the LC-MS/MS
peptide data, see Table S3A and ii) intact nMPO was infused
into a modified Q-Exactive (Thermo Scientific) operating in
positive ion polarity via nano-ESI using custom-made gold-
coated capillaries (75). Data were processed with Xcalibur v2.2
(Thermo Scientific), spectra deconvoluted with UniDec (76)
and annotated using in-house software.
Intact nMPO was analysed using single-molecule mass
photometry as described (44). Coverslips were assembled for
sample delivery using silicone CultureWell gaskets (Grace Bio-
Labs). Data were acquired, processed and analysed using
in-house software (43), see Extended experimental procedures
for details.
Visualisation, modelling, molecular dynamics, solvent
accessibility and sequence alignments
Human diprotomeric MPO (PDBID, 1D2V) was used for
visualisation and modelling. Signature N-glycans were added
in silico using the Carbohydrate and Glycoprotein builders
within GLYCAM-Web (http://glycam.org) to mimic nMPO
(WT), Endo H-treated nMPO (P1), the hyper-truncated
Asn355-/Asn391-glycophenotype that was found to be
elevated in Se/Pl-MPO (P2) and an MPO glycoform with semi-
truncated glycans at Asn355 and Asn391 (P3), see Table S10
for overview. The per-residue solvent accessibilities, root
mean squared deviation/fluctuation (RMSD/RMSF) and sec-
ondary structures were calculated using Cpptraj (AmberTools
18), plotted with Gnuplot 5.2 and visualised using VMD 1.9.3.
Snapshots from the molecular dynamics (MD) simulations of
WT- and P1-MPO were structurally aligned to the
ceruloplasmin–MPO complex (4EJX) via the MPO protein
backbone.
Five crystal structures of MPO (PDBID, 1D2V, 1CXP,
1DNU, 1DNW, 5FIW) were used to assess the relative solvent
accessibilities to the Asn residue of all sequons of monop-
rotomeric MPO and to the β1,2-GlcNAc of FA1-glycans at
Asn323, Asn483 and Asn729 of mono- and diprotomeric MPO
using NACCESS (5 Å radii probe) (77).
Sequence alignments of human MPO (P05164) to (i) the
human peroxidase family including eosinophil peroxidase
(P11678), lactoperoxidase (P22079) and thyroid peroxidase12 J. Biol. Chem. (2021) 296 100144(P07202) and (ii) MPO from key mammalian species including
mouse MPO (P11247), macaque MPO (F7BAA9), porcine
MPO (K7GRV6) and bovine MPO (A6QPT4, all downloaded
July 2020) were performed using T-Coffee (http://tcoffee.crg.
cat/apps/tcoffee) and Boxshade (http://www.ch.embnet.org/
software/BOX_form), see Extended experimental procedures
for details.
Endoglycosidase H-treatment of nMPO
Intact nMPO was incubated with or without Streptomyces
plicatus endoglycosidase H (Endo H, Promega) under native
conditions, 37 C, 16 h. All samples including controls con-
taining only Endo H were used immediately for activity and
inhibition profiling and structural characterisation, see
Extended experimental procedures for details.
Chlorination and oxidation activity and ceruloplasmin-
mediated inhibition of MPO
Three independent enzyme activity assays designated ac-
tivity assay 1–3 were carried out to establish the chlorination
and oxidation activity of the granule-separated MPO in crude
protein mixtures and of the isolated Endo H-treated and un-
treated nMPO.
Specifically, the chlorination activities of various MPO gly-
coforms and controls were determined by the formation of
HOCl captured via taurine per time using HOCl standard
curves (activity assay 1) (78). Reactions were initiated by
sequential addition of taurine and H2O2 (Sigma), stopped by
catalase (Sigma) and measured at 650 nm after addition of
3,30,5,50-tetramethylbenzidine (TMB, Sigma). The relative
oxidation activities of various MPO glycoforms and controls
were determined using a TMB assay (activity assay 2) and an o-
phenylenediamine assay (activity assay 3). Reactions were
initiated by the addition of TMB or o-phenylenediamine
(Sigma), quenched after incubation with sulphuric acid
(Sigma) and the colour intensity measured at 450 nm or
492 nm, respectively. Readings were adjusted based on water
and Endo H controls, Table S9.
Ceruloplasmin-mediated inhibition of the MPO enzyme
activity was determined using activity assay 1–3. Endo H-
treated and untreated nMPO and controls were incubated with
and without human serum-derived ceruloplasmin (P00450,
Lee BioSolutions) in technical triplicates prior to activity
measurements. Readings were adjusted based on water, Endo
H and ceruloplasmin controls, see Extended experimental
procedures for details of the MPO activity assays and cerulo-
plasmin inhibition experiments.
Circular dichroism profiling and temperature stability
Circular dichroism (CD) data of nMPO, Endo H-treated
nMPO and controls were collected in technical duplicates
using 1 mm-pathlength cuvettes (Starna Scientific) in a Jasco J-
1500 spectropolarimeter. CD spectra were recorded using
260–190 nm scans at pre-melting temperatures (20–50 C).
Thermal stability was determined by monitoring the 208 nm
signal over a temperature range. Readings were baseline
EDITORS’ PICK: The glycobiology of neutrophil myeloperoxidasecorrected based on water and Endo H controls, see Extended
experimental procedures for details.
Data representation and statistics
Significance was tested using one-/two-tailed paired/un-
paired Student’s t-tests. Confidence was designated by *p <
0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, *****p < 0.0005.
ns, non-significant test (p ≥ 0.05). Biological and technical
replicates have been stated for each experiment. Data were
plotted as the mean, while error bars represent their standard
deviation (SD).
Ethics statement
Buffy coats from healthy individuals were provided by The
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Data availability
This study contains Supporting information. Three sup-
porting files have been provided: (1) Supplementary Informa-
tion containing Extended experimental procedures and
Figures S1–S9, (2) Supplementary Tables containing
Tables S1–S13 and (3) Supplementary Data containing Data
S1–S3 (PDF).
The LC-MS/MS raw data files are available via
ProteomeXchange with identifier PXD021131. Username:
reviewer83828@ebi.ac.uk, Password: nOuGDU6Q.
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